In Our View Liquidia Technologies’ LIQ861 has the Potential to Improve the Therapeutic Profile of Trepostinil in Treating PAH by Safely Delivering Higher Doses into the Lungs

Wedbush’s Liana Moussatos discussed Liquidia Technologies, her outperform rating on the stock, and explains how their new drug could help people who suffer from PAH.

For more on Liana Moussatos’ comments: Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020